Table 3 Associations of PITX2 DNA methylation (mPITX2) with clinicopathological parameters of PCa patients from the training cohort (n = 498)

All patients

498 (100 %)

32.9

Mean/median follow-up (months)

22/16

Age (years)

0.001^a

 ≤60

224 (45.0 %)

31.0

128 (57.1 %)

96 (42.9 %)

 >60

274 (55.0 %)

35.2

135 (49.1 %)

140 (50.9 %)

 Unknown

0 (0.0 %)

T category

0.043^a

 pT1/2

188 (37.8 %)

25.7

137 (70.3 %)

58 (29.7 %)

 pT3/4

293 (58.8 %)

37.5

126 (41.4 %)

178 (58.6 %)

 Unknown

17 (3.4 %)

ISUP Gleason grading group

<0.001^b

 1 (<7)

45 (9 %)

28.0

31 (68.9 %)

14 (31.1 %)

 2 (3 + 4)

147 (29.5 %)

28.6

95 (64.2 %)

53 (35.8 %)

 3 (4 + 3)

101 (20.3 %)

31.5

55 (54.5 %)

46 (45.5 %)

 4 (=8)

64 (12.9 %)

34.1

33 (51.6 %)

31 (48.4 %)

 5 (>8)

141 (28.3 %)

41.0

49 (34.8 %)

92 (65.2 %)

 Unknown

0 (0.0 %)

Surgical margin

<0.001^a

 R0

318 (63.9 %)

30.8

180 (56.8 %)

137 (43.2 %)

 R1

152 (30.5 %)

37.0

68 (44.7 %)

84 (55.3 %)

 Unknown

28 (5.6 %)

Nodal status

0.19^a

 pN0

349 (70.1 %)

32.3

184 (53.0 %)

163 (47.0 %)

 pN1

79 (15.8 %)

36.6

32 (40.5 %)

47 (49.5 %)

 Unknown

70 (14.1 %)

Pre-surgical PSA (ng/ml)

0.36^b

 0–4

53 (10.6 %)

29.5

31 (58.5 %)

122 (41.5 %)

 4–10

286 (57.5 %)

32.9

150 (52.4 %)

136 (47.6 %)

 >10

156 (31.3 %)

34.3

79 (50.3 %)

78 (49.7 %)

 Unknown

3 (0.6 %)

ERG fusion^c

<0.001^a

 Negative

178 (35.8 %)

28.0

122 (62.9 %)

66 (37.1 %)

 Positive

152 (30.5 %)

37.2

69 (45.4 %)

83 (54.6 %)

 Unknown

168 (33.7 %)

AR score

0.15^a

 Negative

246 (49.4 %)

30.6

140 (56.9 %)

106 (43.1 %)

 Positive

84 (16.9 %)

34.6

41 (48.8 %)

43 (51.2 %)

 Unknown

186 (33.7 %)